The antiviral medication Tamiflu shortened the length of time patients experienced flu symptoms, and reduced rates of complications and hospitalizations from the virus, a new study finds. But it did not have an effect on those with flu-like symptoms who did not have the flu.
Harvard Pilgrim Health Care, one of the largest not-for-profit health insurers in New England, said it will save millions of dollars in hepatitis C drug costs through its negotiated pricing discount from pharmaceutical giant Gilead Sciences.
The nation's largest healthcare organizations predicted a profitable 2015 at the annual J.P. Morgan Healthcare Conference in San Francisco. They forecast that the biggest cloud on the horizon—the pending U.S. Supreme Court case challenging the Obamacare premium subsidies—would pass...
Aetna has agreed to a deal with Gilead Sciences to give preference to the drugmaker's hepatitis C drugs. It's the fourth straight agreement where a payer or benefits manager has chosen Gilead over competitor AbbVie.
Humana acknowledged late Tuesday it has an exclusive deal to offer Gilead Sciences' hepatitis C drugs to its members. The company's announcement is the latest in a string of bargaining battles between health insurers and pharmacy benefits managers and pharmaceutical companies.
Exclusivity deals for hepatitis C drugs by pharmacy benefit managers and a major health plan have raised concerns that the decision of which drug is best for a patient is being taken away from clinicians.
The battle over market share for the three newest and costliest hepatitis C drugs continues. And this time, Gilead Sciences wins the round. CVS Health, one of the nation's largest pharmacy benefit managers, said this week it will exclusively offer patients seeking treatment for hepatitis C the...
The Food and Drug Administration approved 41 first-of-a-kind drugs in 2014, including a record number of medicines for rare diseases, pushing the agency's annual tally of drug approvals to its highest level in 18 years.
Health insurers have lots of challenges ahead as they monitor the development of the healthcare reform law's marketplaces.
Healthcare providers and insurers were busy implementing healthcare reform in 2014, millions of uninsured Americans gained coverage, and healthcare spending growth remained modest even as partisan warfare over the Patient Protection and Affordable Care Act continued in full force.
The Food and Drug Administration on Friday approved Viekira Pak, a combination of pills that becomes the fourth treatment the agency has approved in the past year to treat hepatitis C.
A not-for-profit organization created and funded by the healthcare reform law plans to spend up to $50 million on comparative effectiveness research for hepatitis C treatments just as the government is set to approve the third drug in a new breed of treatment regimens.